Skip to main content

Advertisement

Log in

Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis

  • Topic Review
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Introduction

Despite aggressive treatment with chemoradiotherapy and maximum surgical resection, survival in patients with glioblastoma (GBM) remains poor. Ongoing efforts are aiming to prolong the lifespan of these patients; however, disparities exist in reported survival values with lack of clear evidence that objectively examines GBM survival trends. We aim to describe the current status and advances in the survival of patients with GBM, by analyzing median overall survival through time and between treatment modalities.

Methods

A systematic review was conducted according to PRISMA guidelines to identify articles of newly diagnosed glioblastoma from 1978 to 2018. Full-text glioblastoma papers with human subjects, ≥ 18 years old, and n ≥ 25, were included for evaluation.

Results

The central tendency of median overall survival (MOS) was 13.5 months (2.3–29.6) and cumulative 5-year survival was 5.8% (0.01%–29.1%), with a significant difference in survival between studies that predate versus postdate the implementation of temozolomide and radiation, [12.5 (2.3–28) vs 15.6 (3.8–29.6) months, P < 0.001]. In clinical trials, bevacizumab [18.2 (10.6–23.0) months], tumor treating fields (TTF) [20.7 (20.5–20.9) months], and vaccines [19.2 (15.3–26.0) months] reported the highest central measure of median survival.

Conclusion

Coadministration with radiotherapy and temozolomide provided a statistically significant increase in survival for patients suffering from glioblastoma. However, the natural history for GBM remains poor. Therapies including TTF pooled values of MOS and provide means of prolonging the survival of GBM patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88. https://doi.org/10.1093/neuonc/nox158

    Article  PubMed  PubMed Central  Google Scholar 

  2. Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037. https://doi.org/10.1056/NEJMoa1611977

    Article  CAS  PubMed  Google Scholar 

  3. Raysi Dehcordi S, De Paulis D, Marzi S, Ricci A, Cimini A, Cifone MG, Galzio RJ (2012) Survival prognostic factors in patients with glioblastoma: our experience. J Neurosurg Sci 56:239–245

    CAS  PubMed  Google Scholar 

  4. Roberts PS, Nuno M, Sherman D, Asher A, Wertheimer J, Riggs RV, Patil CG (2014) The impact of inpatient rehabilitation on function and survival of newly diagnosed patients with glioblastoma. Pm r 6:514–521. https://doi.org/10.1016/j.pmrj.2013.12.007

    Article  PubMed  Google Scholar 

  5. Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, Quinones-Hinojosa A (2011) Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. J Neurosurg 114:587–594. https://doi.org/10.3171/2010.8.Jns1081

    Article  PubMed  Google Scholar 

  6. Chaichana KL, Halthore AN, Parker SL, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa A (2011) Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. J Neurosurg 114:604–612. https://doi.org/10.3171/2010.4.Jns091340

    Article  PubMed  Google Scholar 

  7. Hulshof MC, Koot RW, Schimmel EC, Dekker F, Bosch DA, Gonzalez Gonzalez D (2001) Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution. Strahlenther Onkol 177:283–290

    Article  CAS  PubMed  Google Scholar 

  8. Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, Stupp R (2019) Newly diagnosed glioblastoma: a review on clinical management. Oncology (Williston Park) 33:91–100

    Google Scholar 

  9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330

    Article  CAS  PubMed  Google Scholar 

  10. Cantrell JN, Waddle MR, Rotman M, Peterson JL, Ruiz-Garcia H, Heckman MG, Quinones-Hinojosa A, Rosenfeld SS, Brown PD, Trifiletti DM (2019) Progress toward long-term survivors of glioblastoma. Mayo Clin Proc 94:1278–1286. https://doi.org/10.1016/j.mayocp.2018.11.031

    Article  PubMed  Google Scholar 

  11. Tykocki T, Eltayeb M (2018) Ten-year survival in glioblastoma A systematic review. J Clin Neurosci 54:7–13. https://doi.org/10.1016/j.jocn.2018.05.002

    Article  PubMed  Google Scholar 

  12. Chaudhry NS, Shah AH, Ferraro N, Snelling BM, Bregy A, Madhavan K, Komotar RJ (2013) Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century. Cancer Invest 31:287–308. https://doi.org/10.3109/07357907.2013.789899

    Article  PubMed  Google Scholar 

  13. Thomas AA, Brennan CW, DeAngelis LM, Omuro AM (2014) Emerging therapies for glioblastoma. JAMA Neurol 71:1437–1444. https://doi.org/10.1001/jamaneurol.2014.1701

    Article  PubMed  Google Scholar 

  14. Jain KK (2018) A critical overview of targeted therapies for glioblastoma. Front Oncol 8:419. https://doi.org/10.3389/fonc.2018.00419

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lim M, Xia Y, Bettegowda C, Weller M (2018) Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 15:422–442. https://doi.org/10.1038/s41571-018-0003-5

    Article  CAS  PubMed  Google Scholar 

  16. Ramos AD, Magge RS, Ramakrishna R (2018) Molecular pathogenesis and emerging treatment for glioblastoma. World Neurosurg 116:495–504. https://doi.org/10.1016/j.wneu.2018.04.021

    Article  PubMed  Google Scholar 

  17. Chaichana K, Parker S, Olivi A, Quinones-Hinojosa A (2010) A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg 112:997–1004. https://doi.org/10.3171/2009.9.Jns09805

    Article  PubMed  Google Scholar 

  18. Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, Brem H, Quinones-Hinojosa A (2011) Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol 18:239–245. https://doi.org/10.1245/s10434-010-1242-6

    Article  PubMed  Google Scholar 

  19. Chaichana KL, McGirt MJ, Frazier J, Attenello F, Guerrero-Cazares H, Quinones-Hinojosa A (2008) Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection. J Neurooncol 89:219–224. https://doi.org/10.1007/s11060-008-9609-2

    Article  PubMed  Google Scholar 

  20. Oxford Centre for evidence-based medicine: levels of evidence (March 2009). https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/

  21. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316. https://doi.org/10.1001/jama.2017.18718

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543. https://doi.org/10.1001/jama.2015.16669

    Article  CAS  PubMed  Google Scholar 

  23. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, Zagzag D, Eagan P, Gruber ML (2012) A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 116:341–345. https://doi.org/10.3171/2011.9.Jns11656

    Article  CAS  PubMed  Google Scholar 

  24. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS (2011) The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:4119–4124. https://doi.org/10.1158/1078-0432.Ccr-11-0120

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345

    Article  CAS  PubMed  Google Scholar 

  27. Snelling L, Miyamoto CT, Bender H, Brady LW, Steplewski Z, Class R, Emrich J, Rackover MA (1995) Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma 14:111–114. https://doi.org/10.1089/hyb.1995.14.111

    Article  CAS  PubMed  Google Scholar 

  28. Wang Y, Pan L, Sheng XF, Chen S, Dai JZ (2016) Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. Asia Pac J Clin Oncol 12:e23–29. https://doi.org/10.1111/ajco.12166

    Article  PubMed  Google Scholar 

  29. Solomon MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domingez R, Alert J, Marinello JJ, Catala M, Griego MG, Martell JA, Luaces PL, Ballesteros J, Castro N, Bach F, Crombet T (2013) Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 13:299. https://doi.org/10.1186/1471-2407-13-299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 17:854–861. https://doi.org/10.1093/neuonc/nou348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:1373–1385. https://doi.org/10.1016/s1470-2045(17)30517-x

    Article  CAS  PubMed  Google Scholar 

  32. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, Menten J, Clement P, Debiec-Rychter M, De Vleeschouwer S (2012) Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 61:2033–2044. https://doi.org/10.1007/s00262-012-1261-1

    Article  CAS  PubMed  Google Scholar 

  33. Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, Lindner J, Kutscher S, Hilf N, McGuigan L, Peters J, Hill K, Schoor O, Singh-Jasuja H, Halford SE, Ritchie JW (2016) A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res 22:4776–4785. https://doi.org/10.1158/1078-0432.Ccr-16-0506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, DePriest MC (2009) Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 32:914–919. https://doi.org/10.1097/CJI.0b013e3181b2910f

    Article  PubMed  Google Scholar 

  35. Westphal M, Yla-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, Kinley J, Kay R, Ram Z (2013) Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol 14:823–833. https://doi.org/10.1016/s1470-2045(13)70274-2

    Article  CAS  PubMed  Google Scholar 

  36. Ursu R, Carpentier A, Metellus P, Lubrano V, Laigle-Donadey F, Capelle L, Guyotat J, Langlois O, Bauchet L, Desseaux K, Tibi A, Chinot O, Lambert J, Carpentier AF (2017) Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study. Eur J Cancer 73:30–37. https://doi.org/10.1016/j.ejca.2016.12.003

    Article  CAS  PubMed  Google Scholar 

  37. Noch EK, Ramakrishna R, Magge R (2018) Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance. World Neurosurg 116:505–517. https://doi.org/10.1016/j.wneu.2018.04.022

    Article  PubMed  Google Scholar 

  38. Braun K, Ahluwalia MS (2017) Treatment of Glioblastoma in Older Adults. Curr Oncol Rep 19:81. https://doi.org/10.1007/s11912-017-0644-z

    Article  CAS  PubMed  Google Scholar 

  39. Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N (2018) Current challenges and opportunities in treating glioblastoma. Pharmacol Rev 70:412–445. https://doi.org/10.1124/pr.117.014944

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ (2019) Challenges to curing primary brain tumours. Nat Rev Clin Oncol 16:509–520. https://doi.org/10.1038/s41571-019-0177-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Yang W, Xu T, Garzon-Muvdi T, Jiang C, Huang J, Chaichana KL (2018) Survival of ventricular and periventricular high-grade gliomas: a surveillance, epidemiology, and end results program-based study. World Neurosurg 111:e323–e334. https://doi.org/10.1016/j.wneu.2017.12.052

    Article  PubMed  Google Scholar 

  42. Woo P, Ho J, Lam S, Ma E, Chan D, Wong WK, Mak C, Lee M, Wong ST, Chan KY, Poon WS (2018) A comparative analysis of the usefulness of survival prediction models for patients with glioblastoma in the temozolomide era: the importance of methylguanine methyltransferase promoter methylation, extent of resection, and subventricular zone location. World Neurosurg 115:e375–e385. https://doi.org/10.1016/j.wneu.2018.04.059

    Article  PubMed  Google Scholar 

  43. Fatehi M, Hunt C, Ma R, Toyota BD (2018) Persistent disparities in survival for patients with glioblastoma. World Neurosurg 120:e511–e516. https://doi.org/10.1016/j.wneu.2018.08.114

    Article  PubMed  Google Scholar 

  44. Shah BK, Bista A, Sharma S (2016) Survival trends in elderly patients with glioblastoma in the United States: a population-based study. Anticancer Res 36:4883–4886. https://doi.org/10.21873/anticanres.11052

    Article  PubMed  Google Scholar 

  45. Witthayanuwat S, Pesee M, Supaadirek C, Supakalin N, Thamronganantasakul K, Krusun S (2018) Survival analysis of glioblastoma multiforme. Asian Pac J Cancer Prev 19:2613–2617. https://doi.org/10.22034/apjcp.2018.19.9.2613

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Teo M, Martin S, Owusu-Agyemang K, Nowicki S, Clark B, Mackinnon M, Stewart W, Paul J, St George J (2014) A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime. Br J Neurosurg 28:351–355. https://doi.org/10.3109/02688697.2013.847170

    Article  PubMed  Google Scholar 

  47. Balana C, De Las PR, Sepulveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Perez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villa S (2016) Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol 127:569–579. https://doi.org/10.1007/s11060-016-2065-5

    Article  CAS  PubMed  Google Scholar 

  48. Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, Grunnet K, Ask A, Costa JC, Kristiansen C, Thomsen C, Poulsen HS, Lassen U (2014) Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: a randomized phase II study. Acta Oncol 53:939–944. https://doi.org/10.3109/0284186x.2013.879607

    Article  CAS  PubMed  Google Scholar 

  49. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE 2nd, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729. https://doi.org/10.1200/jco.2010.28.6963

    Article  PubMed  PubMed Central  Google Scholar 

  50. Rick J, Chandra A, Aghi MK (2018) Tumor treating fields: a new approach to glioblastoma therapy. J Neurooncol 137:447–453. https://doi.org/10.1007/s11060-018-2768-x

    Article  PubMed  Google Scholar 

  51. Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y (2007) Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA 104:10152–10157. https://doi.org/10.1073/pnas.0702916104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH (2012) NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192–2202. https://doi.org/10.1016/j.ejca.2012.04.011

    Article  PubMed  Google Scholar 

  53. Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL (2014) Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 23:1985–1996. https://doi.org/10.1158/1055-9965.Epi-14-0275

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

AQH was supported by the Mayo Clinic Professorship and a Clinician Investigator award, the NIH (R43CA221490, R01CA200399, R01CA195503, and R01CA216855) as well as the Florida Department of Health Cancer Research Chair Fund.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kaisorn L. Chaichana.

Ethics declarations

Conflict of interest

The authors report no funding sources or conflict of interests concerning the materials or methods used in the study or the findings specified in this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 245 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marenco-Hillembrand, L., Wijesekera, O., Suarez-Meade, P. et al. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol 147, 297–307 (2020). https://doi.org/10.1007/s11060-020-03451-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-020-03451-6

Keywords

Navigation